Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
-
Schedule 13G/A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
FAQ
How many Travere Therapeutics (TVTX) SEC filings are available on StockTitan?
StockTitan tracks 183 SEC filings for Travere Therapeutics (TVTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Travere Therapeutics (TVTX)?
The most recent SEC filing for Travere Therapeutics (TVTX) was filed on August 6, 2025.